S. Dawood, S. D. Merajver, and P. Viens, International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Ann Oncol, vol.22, pp.515-523, 2011.

D. W. Miles, V. Dieras, and J. Cortes, First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients, Ann Oncol, vol.24, pp.2773-2780, 2013.

G. Von-minckwitz, S. Loibl, and M. Untch, Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2negative primary breast cancer (GBG 44-GeparQuinto), Ann Oncol, vol.25, pp.2363-2372, 2014.

H. D. Bear, G. Tang, and P. Rastogi, Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial, Lancet Oncol, vol.16, pp.1037-1048, 2015.

W. J. Janni, B. Rack, and L. W. Terstappen, Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer, Clin Cancer Res, vol.22, pp.2583-2593, 2016.

J. Y. Pierga, F. C. Bidard, and C. Mathiot, Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial, Clin Cancer Res, vol.14, pp.7004-7010, 2008.

S. Riethdorf, V. Muller, and L. Zhang, Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial, Clin Cancer Res, vol.16, pp.2634-2645, 2010.

J. Y. Pierga, T. Petit, and T. Delozier, Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study, Lancet Oncol, vol.13, pp.375-384, 2012.

M. Mego, A. Giordano, D. Giorgi, and U. , Circulating tumor cells in newly diagnosed inflammatory breast cancer, Breast Cancer Res, vol.17, issue.2, 2015.

J. Y. Pierga, T. Petit, and C. Levy, Pathological response and circulating tumor cell count identifies treated HER2þ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data, Clin Cancer Res, vol.21, pp.1298-1304, 2015.

F. Bertucci, M. Fekih, and A. Autret, Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study, Lancet Oncol, vol.17, pp.600-611, 2016.

C. S. Hall, M. Karhade, and B. A. Laubacher, Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer, J Natl Cancer Inst, vol.107, 2015.

F. C. Bidard, C. Mathiot, and A. Degeorges, Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy, Ann Oncol, vol.21, pp.1765-1771, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00508113

J. Y. Pierga, D. Hajage, and T. Bachelot, High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients, Ann Oncol, vol.23, pp.618-624, 2012.

S. Riethdorf, V. Mueller, and O. Mauermann, Changes in circulating tumor and endothelial cells in peripheral blood of patients treated in the neoadjuvant chemotherapy plus targeted treatment breast cancer study "GeparQuinto, Cancer Res, vol.70, pp.4-06, 2010.

S. J. Conley, E. Gheordunescu, and P. Kakarala, Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia, Proc Natl Acad Sci U S A, vol.109, pp.2784-2789, 2012.

S. Kasimir-bauer, O. Hoffmann, and D. Wallwiener, Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells, Breast Cancer Res, vol.14, p.15, 2012.

P. Gazzaniga, C. Raimondi, and A. Gradilone, Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero, Ann Oncol, vol.22, pp.1929-1930, 2011.

C. Nicolazzo, I. Massimi, and L. V. Lotti, Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells, Chin J Cancer Res, vol.27, pp.491-496, 2015.

F. C. Bidard, C. Proudhon, and J. Y. Pierga, Circulating tumor cells in breast cancer, Mol Oncol, vol.10, pp.418-430, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-00749450

F. Bertucci, P. Finetti, and C. Colpaert, PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy, Oncotarget, vol.6, pp.13506-13519, 2015.

M. Mazel, W. Jacot, and K. Pantel, Frequent expression of PD-L1 on circulating breast cancer cells, Mol Oncol, vol.9, pp.1773-1782, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162382